Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations ligelizumab - IgE inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT05024058 PEARL-PROVOKE (CQGE031E12301) CINDU Phase 3 438 1. Change from baseline in Total Fric Score in participants with symptomatic dermographism Arm 1: Experimental Ligelizumab low dose, symptomatic dermographism group Arm 2: Experimental Ligelizumab high dose, symptomatic dermographism Arm 3: Placebo Comparator. Placebo SC q4W, symptomatic dermographism Arm 4: Experimental Ligelizumab low dose, cold urticaria Arm 5: Experimental Ligelizumab high dose, cold urticaria Arm 6: Placebo Comparator: Placebo SC q4w, cold urticaria Arm 7: Experimental Ligelizumab high dose, cholinergic urticaria Arm 8: Placebo Comparator: Placebo SC q4w, cholinergic urticaria Adolescents and adults with chronic inducible urticaria who remain symptomatic despite treatment with H1- Antihistamines Target Patients Read-out Milestone(s) Publication 2024 TBD NCT04984876 PEANUT (CQGE031G12301) Food allergy Phase 3 486 1. Proportion of participants who can tolerate a single dose of ≥ 600 mg (1044 mg cumulative tolerated dose) of peanut protein without dose-limiting symptoms at Week 12 Arm 1: Experimental igelizumab 240 mg subcutaneous injection for 52 weeks Arm 2: Experimental ligelizumab 120 mg subcutaneous injection for 52 weeks Arm 3: Experimental Placebo 8 weeks and ligelizumab 120 mg Arm 4: Placebo subcutaneous injection for first 8 weeks and ligelizumab 120 mg subcutaneous injection for 44 weeks Arm 5: Experimental Placebo 16 weeks and ligelizumab 120 mg/240 mg subcutaneous injection for 36 weeks Arm 6: Experimental Placebo 8 weeks and ligelizumab 240 mg subcutaneous injection for 44 weeks Participants with a medically confirmed diagnosis of IgE-mediated peanut allergy 2025 90 Investor Relations | Q4 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation